Aptissen SA / MD Biologix Partnership
June 06, 2023
Aptissen SA and MD Biologix have entered into an exclusive agreement for the distribution of Synolis VA in Canada.
This agreement grants MD Biologix the immediate rights to market and sell the product in Canada, providing a stable and consistent supply of Synolis VA for doctors via the company’s established clinical supply network.
Synolis VA (Visco-Antalgic) is a Health Canada approved intra-articular joint product indicated for the treatment of knee osteoarthritis, which is estimated to affect more than 3.9 million Canadians aged 20 years and older.
The product comes in both 2ml and 4ml formulations and contains a proprietary blend of high-molecular weight Hyaluronic Acid with Sorbitol that mimics the natural properties of synovial fluid.
On the partnership, “We are thrilled to work with Aptissen to bring Synolis VA into Canada. It is an exceptionally high-quality product that aligns with our current portfolio and commitment to bring innovative medical technology to Canadian doctors.” Murray Downs, President of MD Biologix.
Carole Scheibli, CEO of Aptissen S.A. added “We are very excited by this partnership with MD Biologix. We believe that their science-based approach and strong connections in the clinical community will allow Synolis VA to become a major player in the Canadian viscosupplementation market”.
If you are interested in accessing Synolis VA for your patients, please contact:
Connor Downs | MDBiologix | email@example.com
MDBiologix is an industry leader in Regenerative Medicine that brings innovative, life-changing therapies to patients looking to recover from pain, trauma, or the natural aging process. Its products are developed and manufactured by some of the world’s most advanced medical device companies, and together with its complete clinical support allow physicians to offer new treatment options to patients that can improve their quality of life.
For more information, please see https://www.mdbiologix.com/.
About Aptissen S.A.
Aptissen S.A. is a Swiss company specialized in the development and commercialization of biopolymer-based medical devices in the musculoskeletal field. Aptissen’s founders have more than 25 years of experience in developing the best quality injectable products which meet both patients and doctors expectations.
For more information, please see https://www.aptissen.com/.